The integration of our results suggests that the simultaneous regulation of multiple pathways and preferential sensitivity in ErbB2+ breast cancer cells makes ganetespib a promising therapeutic agent for refractory ErbB2+ breast cancers. The gene discussed is ERBB2; the disease is breast carcinoma.